Features of proline stabilization include2:

  • Reduced IgG aggregation
  • Reduced dimer formation
  • Minimized fragmentation
  • Prevention of solution discoloration
  • Room-temperature storage
Up to 36-month room temperature (up to 25°C [77°F]) storage, as indicated by the expiration date printed on the outer carton and vial label.

How proline works

Proline interacts with hydrophobic groups in the IgG molecule, thereby reducing protein-protein association and dimerization; in other words, it stabilizes IgG molecules as monomers.2 The images below show dimer formation in IgG solutions with proline and without proline.

Dimerization can occur without proline

Dimer formation occurs without proline

In solution, IgG molecules (shown in blue) reversibly bind to each other (circled).2

Proline inhibits dimer formation and stabilizes IgG molecules

Proline reduces dimer formation

Proline may shield IgG molecules from binding together.2

Proline is rapidly cleared from circulation and does not accumulate after treatment.*3 Privigen is contraindicated in patients with hyperprolinemia.

May be appropriate in a wide range of patients

Privigen may be an option for patients with latex allergy, sensitivity to preservatives, or those who need to limit their sugar intake

graphic showing no sugar, no latex, no preservatives, only traces of sodium

Designed for stability, Privigen is also safe and effective

See how Privigen did in clinical studies

View the studies

References: 1. Cramer M, Frei R, Sebald A, Maeder M. Stability over 36 months of new liquid 10% polyclonial immunoglobulin product (IgPro10. Privigen®) stabilized with L-proline. Vox Sang. 2009;96(3):219-225. 2. Bolli R, Woodtli K, Bärtschi M, Höfferer L, Lerch P. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biological. 2010;38(1):150-157. 3. Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010;30(5):734-745.

You are now leaving the current website.

Do you want to continue?